DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruelisauer, A.
Right arrow Articles by Lemaire, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruelisauer, A.
Right arrow Articles by Lemaire, M.

Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration

A Bruelisauer, R Kawai, P Misslin and M Lemaire

Sandoz Pharma Ltd., Basel, Switzerland.

The absorption and disposition of SDZ IMM 125, a new derivative of the cyclosporine family, were studied in rats after oral, subcutaneous, or intravenous dosing. The absolute bioavailability of 53% observed after a single oral dose of 10 mg/kg was variable and similar to that observed with cyclosporine A. The bioavailability was not modified during 21 days of daily treatment. The fraction of SDZ IMM 125 bound to plasma proteins was moderate (70% vs. 95% for cyclosporine A), whereas the uptake by blood cells was considerably higher than that of cyclosporine A varying from 80% at 50 ng/ml to 30% at 10,000 ng/ml. SDZ IMM 125 distributes extensively in most tissues except in brain; multiple oral administration does not modify the tissue distribution and indicates that there is no drug accumulation. The tissue distribution of SDZ IMM 125 is lower than that of cyclosporine A; the volume of distribution of this drug (2.6 liters/kg) is roughly half that of cyclosporine A, which is consistent with the lower lipophilicity of this compound. The systemic clearance of SDZ IMM 125 is relatively low (1.3 ml/min) and comparable to that of cyclosporine A. The excretion of SDZ IMM 125 occurs essentially through the liver via the bile; biliary and urinary excretion of unchanged drug represents 18% and 7% of the dose, respectively. The significant excretion of unchanged drug in both bile and urine represents a major difference compared with cyclosporine A, which is not excreted as unchanged drug to any extent.

Volume 22, Issue 2, pp. 194-199, 03/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
A. E. M. Vickers, R. M. Jimenez, M. C. Spaans, V. Pflimlin, R. L. Fisher, and K. Brendel
Human and Rat Lung Biotransformation of Cyclosporin A and Its Derivatives Using Slices and Bronchial Epithelial Cells
Drug Metab. Dispos., July 1, 1997; 25(7): 873 - 880.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics.